Enteric-Coated Mycophenolate Sodium

Phase 3Completed

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Denovo Renal Transplantation

Conditions

Denovo Renal Transplantation

Trial Timeline

Mar 1, 2002 → Jul 1, 2005

NCT ID

NCT00239031

About Enteric-Coated Mycophenolate Sodium

Enteric-Coated Mycophenolate Sodium is a phase 3 stage product being developed by Novartis for Denovo Renal Transplantation. The current trial status is completed. This product is registered under clinical trial identifier NCT00239031. Target conditions include Denovo Renal Transplantation.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (7)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01467011	Pre-clinical	Completed	Dec 1, 2010	Dec 1, 2013	End Stage Liver Disease
NCT00351377	Phase 3	Completed	Jun 1, 2006	Jun 1, 2009	Autoimmune Disease
NCT00171379	Phase 3	Completed	Mar 1, 2004	Jun 1, 2005	Prevention of Acute Rejection After Kidney Transplantation
NCT00171392	Phase 3	Completed	Mar 1, 2004	Jun 1, 2005	Prevention of Acute Rejection After Kidney Transplantation
NCT00239057	Phase 3	Completed	May 1, 2002	Jan 1, 2005	Maintenance Renal Transplantation
NCT00239031	Phase 3	Completed	Mar 1, 2002	Jul 1, 2005	Denovo Renal Transplantation
NCT00574743	Approved	Completed	Jan 1, 2002	—	Heart Transplantation

Other Products from Novartis

LCZ696Approved

zoledronic acidApproved

NateglinideApproved

TenofovirApproved

FTY720Approved